nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—Paget's disease of bone—ankylosing spondylitis	0.488	0.522	CtDrD
Zoledronate—osteoporosis—ankylosing spondylitis	0.447	0.478	CtDrD
Zoledronate—Infection—Triamcinolone—ankylosing spondylitis	9.55e-05	0.00146	CcSEcCtD
Zoledronate—Infection—Methylprednisolone—ankylosing spondylitis	9.53e-05	0.00146	CcSEcCtD
Zoledronate—Haematuria—Methotrexate—ankylosing spondylitis	9.49e-05	0.00145	CcSEcCtD
Zoledronate—Shock—Triamcinolone—ankylosing spondylitis	9.46e-05	0.00145	CcSEcCtD
Zoledronate—Insomnia—Prednisolone—ankylosing spondylitis	9.45e-05	0.00145	CcSEcCtD
Zoledronate—Alopecia—Prednisone—ankylosing spondylitis	9.45e-05	0.00145	CcSEcCtD
Zoledronate—Shock—Methylprednisolone—ankylosing spondylitis	9.44e-05	0.00144	CcSEcCtD
Zoledronate—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	9.41e-05	0.00144	CcSEcCtD
Zoledronate—Loss of consciousness—Dexamethasone—ankylosing spondylitis	9.39e-05	0.00144	CcSEcCtD
Zoledronate—Loss of consciousness—Betamethasone—ankylosing spondylitis	9.39e-05	0.00144	CcSEcCtD
Zoledronate—Paraesthesia—Prednisolone—ankylosing spondylitis	9.39e-05	0.00144	CcSEcCtD
Zoledronate—Tachycardia—Triamcinolone—ankylosing spondylitis	9.38e-05	0.00144	CcSEcCtD
Zoledronate—Mental disorder—Prednisone—ankylosing spondylitis	9.37e-05	0.00143	CcSEcCtD
Zoledronate—Tachycardia—Methylprednisolone—ankylosing spondylitis	9.36e-05	0.00143	CcSEcCtD
Zoledronate—Skin disorder—Methylprednisolone—ankylosing spondylitis	9.32e-05	0.00143	CcSEcCtD
Zoledronate—Erythema—Prednisone—ankylosing spondylitis	9.31e-05	0.00142	CcSEcCtD
Zoledronate—Malnutrition—Prednisone—ankylosing spondylitis	9.31e-05	0.00142	CcSEcCtD
Zoledronate—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	9.29e-05	0.00142	CcSEcCtD
Zoledronate—Agranulocytosis—Methotrexate—ankylosing spondylitis	9.29e-05	0.00142	CcSEcCtD
Zoledronate—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	9.27e-05	0.00142	CcSEcCtD
Zoledronate—Convulsion—Betamethasone—ankylosing spondylitis	9.26e-05	0.00142	CcSEcCtD
Zoledronate—Convulsion—Dexamethasone—ankylosing spondylitis	9.26e-05	0.00142	CcSEcCtD
Zoledronate—Hypertension—Dexamethasone—ankylosing spondylitis	9.23e-05	0.00141	CcSEcCtD
Zoledronate—Hypertension—Betamethasone—ankylosing spondylitis	9.23e-05	0.00141	CcSEcCtD
Zoledronate—Myalgia—Dexamethasone—ankylosing spondylitis	9.1e-05	0.00139	CcSEcCtD
Zoledronate—Myalgia—Betamethasone—ankylosing spondylitis	9.1e-05	0.00139	CcSEcCtD
Zoledronate—Anxiety—Dexamethasone—ankylosing spondylitis	9.07e-05	0.00139	CcSEcCtD
Zoledronate—Anxiety—Betamethasone—ankylosing spondylitis	9.07e-05	0.00139	CcSEcCtD
Zoledronate—Discomfort—Betamethasone—ankylosing spondylitis	8.99e-05	0.00138	CcSEcCtD
Zoledronate—Discomfort—Dexamethasone—ankylosing spondylitis	8.99e-05	0.00138	CcSEcCtD
Zoledronate—Hypotension—Methylprednisolone—ankylosing spondylitis	8.96e-05	0.00137	CcSEcCtD
Zoledronate—Pain—Prednisolone—ankylosing spondylitis	8.94e-05	0.00137	CcSEcCtD
Zoledronate—Urinary tract disorder—Methotrexate—ankylosing spondylitis	8.82e-05	0.00135	CcSEcCtD
Zoledronate—Vision blurred—Prednisone—ankylosing spondylitis	8.77e-05	0.00134	CcSEcCtD
Zoledronate—Urethral disorder—Methotrexate—ankylosing spondylitis	8.76e-05	0.00134	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	8.76e-05	0.00134	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	8.74e-05	0.00134	CcSEcCtD
Zoledronate—Anaphylactic shock—Betamethasone—ankylosing spondylitis	8.72e-05	0.00133	CcSEcCtD
Zoledronate—Oedema—Betamethasone—ankylosing spondylitis	8.72e-05	0.00133	CcSEcCtD
Zoledronate—Oedema—Dexamethasone—ankylosing spondylitis	8.72e-05	0.00133	CcSEcCtD
Zoledronate—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	8.72e-05	0.00133	CcSEcCtD
Zoledronate—Insomnia—Triamcinolone—ankylosing spondylitis	8.69e-05	0.00133	CcSEcCtD
Zoledronate—Insomnia—Methylprednisolone—ankylosing spondylitis	8.67e-05	0.00133	CcSEcCtD
Zoledronate—Infection—Dexamethasone—ankylosing spondylitis	8.67e-05	0.00133	CcSEcCtD
Zoledronate—Infection—Betamethasone—ankylosing spondylitis	8.67e-05	0.00133	CcSEcCtD
Zoledronate—Ill-defined disorder—Prednisone—ankylosing spondylitis	8.64e-05	0.00132	CcSEcCtD
Zoledronate—Paraesthesia—Triamcinolone—ankylosing spondylitis	8.63e-05	0.00132	CcSEcCtD
Zoledronate—Feeling abnormal—Prednisolone—ankylosing spondylitis	8.61e-05	0.00132	CcSEcCtD
Zoledronate—Paraesthesia—Methylprednisolone—ankylosing spondylitis	8.61e-05	0.00132	CcSEcCtD
Zoledronate—Anaemia—Prednisone—ankylosing spondylitis	8.6e-05	0.00132	CcSEcCtD
Zoledronate—Shock—Dexamethasone—ankylosing spondylitis	8.58e-05	0.00131	CcSEcCtD
Zoledronate—Shock—Betamethasone—ankylosing spondylitis	8.58e-05	0.00131	CcSEcCtD
Zoledronate—Dyspnoea—Triamcinolone—ankylosing spondylitis	8.57e-05	0.00131	CcSEcCtD
Zoledronate—Nervous system disorder—Dexamethasone—ankylosing spondylitis	8.55e-05	0.00131	CcSEcCtD
Zoledronate—Nervous system disorder—Betamethasone—ankylosing spondylitis	8.55e-05	0.00131	CcSEcCtD
Zoledronate—Agitation—Prednisone—ankylosing spondylitis	8.55e-05	0.00131	CcSEcCtD
Zoledronate—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	8.54e-05	0.00131	CcSEcCtD
Zoledronate—Thrombocytopenia—Betamethasone—ankylosing spondylitis	8.54e-05	0.00131	CcSEcCtD
Zoledronate—Tachycardia—Dexamethasone—ankylosing spondylitis	8.51e-05	0.0013	CcSEcCtD
Zoledronate—Tachycardia—Betamethasone—ankylosing spondylitis	8.51e-05	0.0013	CcSEcCtD
Zoledronate—Angioedema—Prednisone—ankylosing spondylitis	8.5e-05	0.0013	CcSEcCtD
Zoledronate—Dyspepsia—Triamcinolone—ankylosing spondylitis	8.46e-05	0.00129	CcSEcCtD
Zoledronate—Dyspepsia—Methylprednisolone—ankylosing spondylitis	8.44e-05	0.00129	CcSEcCtD
Zoledronate—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	8.43e-05	0.00129	CcSEcCtD
Zoledronate—Hyperhidrosis—Betamethasone—ankylosing spondylitis	8.43e-05	0.00129	CcSEcCtD
Zoledronate—Malaise—Prednisone—ankylosing spondylitis	8.39e-05	0.00128	CcSEcCtD
Zoledronate—Vertigo—Prednisone—ankylosing spondylitis	8.36e-05	0.00128	CcSEcCtD
Zoledronate—Eye disorder—Methotrexate—ankylosing spondylitis	8.35e-05	0.00128	CcSEcCtD
Zoledronate—Syncope—Prednisone—ankylosing spondylitis	8.35e-05	0.00128	CcSEcCtD
Zoledronate—Anorexia—Dexamethasone—ankylosing spondylitis	8.31e-05	0.00127	CcSEcCtD
Zoledronate—Anorexia—Betamethasone—ankylosing spondylitis	8.31e-05	0.00127	CcSEcCtD
Zoledronate—Urticaria—Prednisolone—ankylosing spondylitis	8.3e-05	0.00127	CcSEcCtD
Zoledronate—Cardiac disorder—Methotrexate—ankylosing spondylitis	8.29e-05	0.00127	CcSEcCtD
Zoledronate—Fatigue—Triamcinolone—ankylosing spondylitis	8.29e-05	0.00127	CcSEcCtD
Zoledronate—Fatigue—Methylprednisolone—ankylosing spondylitis	8.27e-05	0.00127	CcSEcCtD
Zoledronate—Pain—Triamcinolone—ankylosing spondylitis	8.22e-05	0.00126	CcSEcCtD
Zoledronate—Loss of consciousness—Prednisone—ankylosing spondylitis	8.18e-05	0.00125	CcSEcCtD
Zoledronate—Hypotension—Dexamethasone—ankylosing spondylitis	8.15e-05	0.00125	CcSEcCtD
Zoledronate—Hypotension—Betamethasone—ankylosing spondylitis	8.15e-05	0.00125	CcSEcCtD
Zoledronate—Angiopathy—Methotrexate—ankylosing spondylitis	8.11e-05	0.00124	CcSEcCtD
Zoledronate—Immune system disorder—Methotrexate—ankylosing spondylitis	8.07e-05	0.00123	CcSEcCtD
Zoledronate—Convulsion—Prednisone—ankylosing spondylitis	8.06e-05	0.00123	CcSEcCtD
Zoledronate—Mediastinal disorder—Methotrexate—ankylosing spondylitis	8.05e-05	0.00123	CcSEcCtD
Zoledronate—Hypertension—Prednisone—ankylosing spondylitis	8.04e-05	0.00123	CcSEcCtD
Zoledronate—Chills—Methotrexate—ankylosing spondylitis	8.02e-05	0.00123	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	7.95e-05	0.00122	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	7.95e-05	0.00122	CcSEcCtD
Zoledronate—Myalgia—Prednisone—ankylosing spondylitis	7.92e-05	0.00121	CcSEcCtD
Zoledronate—Arthralgia—Prednisone—ankylosing spondylitis	7.92e-05	0.00121	CcSEcCtD
Zoledronate—Feeling abnormal—Triamcinolone—ankylosing spondylitis	7.92e-05	0.00121	CcSEcCtD
Zoledronate—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	7.9e-05	0.00121	CcSEcCtD
Zoledronate—Anxiety—Prednisone—ankylosing spondylitis	7.9e-05	0.00121	CcSEcCtD
Zoledronate—Alopecia—Methotrexate—ankylosing spondylitis	7.9e-05	0.00121	CcSEcCtD
Zoledronate—Insomnia—Dexamethasone—ankylosing spondylitis	7.89e-05	0.00121	CcSEcCtD
Zoledronate—Insomnia—Betamethasone—ankylosing spondylitis	7.89e-05	0.00121	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	7.87e-05	0.0012	CcSEcCtD
Zoledronate—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	7.84e-05	0.0012	CcSEcCtD
Zoledronate—Paraesthesia—Betamethasone—ankylosing spondylitis	7.83e-05	0.0012	CcSEcCtD
Zoledronate—Paraesthesia—Dexamethasone—ankylosing spondylitis	7.83e-05	0.0012	CcSEcCtD
Zoledronate—Discomfort—Prednisone—ankylosing spondylitis	7.83e-05	0.0012	CcSEcCtD
Zoledronate—Mental disorder—Methotrexate—ankylosing spondylitis	7.83e-05	0.0012	CcSEcCtD
Zoledronate—Erythema—Methotrexate—ankylosing spondylitis	7.78e-05	0.00119	CcSEcCtD
Zoledronate—Malnutrition—Methotrexate—ankylosing spondylitis	7.78e-05	0.00119	CcSEcCtD
Zoledronate—Hypersensitivity—Prednisolone—ankylosing spondylitis	7.7e-05	0.00118	CcSEcCtD
Zoledronate—Dyspepsia—Betamethasone—ankylosing spondylitis	7.68e-05	0.00117	CcSEcCtD
Zoledronate—Dyspepsia—Dexamethasone—ankylosing spondylitis	7.68e-05	0.00117	CcSEcCtD
Zoledronate—Urticaria—Triamcinolone—ankylosing spondylitis	7.64e-05	0.00117	CcSEcCtD
Zoledronate—Urticaria—Methylprednisolone—ankylosing spondylitis	7.62e-05	0.00117	CcSEcCtD
Zoledronate—Dysgeusia—Methotrexate—ankylosing spondylitis	7.62e-05	0.00117	CcSEcCtD
Zoledronate—Body temperature increased—Triamcinolone—ankylosing spondylitis	7.6e-05	0.00116	CcSEcCtD
Zoledronate—Anaphylactic shock—Prednisone—ankylosing spondylitis	7.6e-05	0.00116	CcSEcCtD
Zoledronate—Oedema—Prednisone—ankylosing spondylitis	7.6e-05	0.00116	CcSEcCtD
Zoledronate—Abdominal pain—Methylprednisolone—ankylosing spondylitis	7.58e-05	0.00116	CcSEcCtD
Zoledronate—Decreased appetite—Dexamethasone—ankylosing spondylitis	7.58e-05	0.00116	CcSEcCtD
Zoledronate—Decreased appetite—Betamethasone—ankylosing spondylitis	7.58e-05	0.00116	CcSEcCtD
Zoledronate—Infection—Prednisone—ankylosing spondylitis	7.55e-05	0.00115	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	7.53e-05	0.00115	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	7.53e-05	0.00115	CcSEcCtD
Zoledronate—Back pain—Methotrexate—ankylosing spondylitis	7.52e-05	0.00115	CcSEcCtD
Zoledronate—Fatigue—Betamethasone—ankylosing spondylitis	7.52e-05	0.00115	CcSEcCtD
Zoledronate—Fatigue—Dexamethasone—ankylosing spondylitis	7.52e-05	0.00115	CcSEcCtD
Zoledronate—Shock—Prednisone—ankylosing spondylitis	7.47e-05	0.00114	CcSEcCtD
Zoledronate—Pain—Dexamethasone—ankylosing spondylitis	7.46e-05	0.00114	CcSEcCtD
Zoledronate—Pain—Betamethasone—ankylosing spondylitis	7.46e-05	0.00114	CcSEcCtD
Zoledronate—Nervous system disorder—Prednisone—ankylosing spondylitis	7.45e-05	0.00114	CcSEcCtD
Zoledronate—Tachycardia—Prednisone—ankylosing spondylitis	7.41e-05	0.00113	CcSEcCtD
Zoledronate—Skin disorder—Prednisone—ankylosing spondylitis	7.38e-05	0.00113	CcSEcCtD
Zoledronate—Hyperhidrosis—Prednisone—ankylosing spondylitis	7.34e-05	0.00112	CcSEcCtD
Zoledronate—Vision blurred—Methotrexate—ankylosing spondylitis	7.33e-05	0.00112	CcSEcCtD
Zoledronate—Anorexia—Prednisone—ankylosing spondylitis	7.24e-05	0.00111	CcSEcCtD
Zoledronate—Ill-defined disorder—Methotrexate—ankylosing spondylitis	7.22e-05	0.0011	CcSEcCtD
Zoledronate—Anaemia—Methotrexate—ankylosing spondylitis	7.19e-05	0.0011	CcSEcCtD
Zoledronate—Feeling abnormal—Betamethasone—ankylosing spondylitis	7.19e-05	0.0011	CcSEcCtD
Zoledronate—Feeling abnormal—Dexamethasone—ankylosing spondylitis	7.19e-05	0.0011	CcSEcCtD
Zoledronate—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	7.13e-05	0.00109	CcSEcCtD
Zoledronate—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	7.13e-05	0.00109	CcSEcCtD
Zoledronate—Hypersensitivity—Triamcinolone—ankylosing spondylitis	7.08e-05	0.00108	CcSEcCtD
Zoledronate—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	7.07e-05	0.00108	CcSEcCtD
Zoledronate—Malaise—Methotrexate—ankylosing spondylitis	7.01e-05	0.00107	CcSEcCtD
Zoledronate—Vertigo—Methotrexate—ankylosing spondylitis	6.99e-05	0.00107	CcSEcCtD
Zoledronate—Leukopenia—Methotrexate—ankylosing spondylitis	6.96e-05	0.00107	CcSEcCtD
Zoledronate—Urticaria—Dexamethasone—ankylosing spondylitis	6.93e-05	0.00106	CcSEcCtD
Zoledronate—Urticaria—Betamethasone—ankylosing spondylitis	6.93e-05	0.00106	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	6.92e-05	0.00106	CcSEcCtD
Zoledronate—Dizziness—Prednisolone—ankylosing spondylitis	6.91e-05	0.00106	CcSEcCtD
Zoledronate—Asthenia—Triamcinolone—ankylosing spondylitis	6.9e-05	0.00106	CcSEcCtD
Zoledronate—Body temperature increased—Dexamethasone—ankylosing spondylitis	6.89e-05	0.00105	CcSEcCtD
Zoledronate—Abdominal pain—Dexamethasone—ankylosing spondylitis	6.89e-05	0.00105	CcSEcCtD
Zoledronate—Abdominal pain—Betamethasone—ankylosing spondylitis	6.89e-05	0.00105	CcSEcCtD
Zoledronate—Body temperature increased—Betamethasone—ankylosing spondylitis	6.89e-05	0.00105	CcSEcCtD
Zoledronate—Asthenia—Methylprednisolone—ankylosing spondylitis	6.88e-05	0.00105	CcSEcCtD
Zoledronate—Insomnia—Prednisone—ankylosing spondylitis	6.87e-05	0.00105	CcSEcCtD
Zoledronate—Paraesthesia—Prednisone—ankylosing spondylitis	6.82e-05	0.00104	CcSEcCtD
Zoledronate—Pruritus—Triamcinolone—ankylosing spondylitis	6.8e-05	0.00104	CcSEcCtD
Zoledronate—Cough—Methotrexate—ankylosing spondylitis	6.79e-05	0.00104	CcSEcCtD
Zoledronate—Pruritus—Methylprednisolone—ankylosing spondylitis	6.79e-05	0.00104	CcSEcCtD
Zoledronate—Convulsion—Methotrexate—ankylosing spondylitis	6.74e-05	0.00103	CcSEcCtD
Zoledronate—Dyspepsia—Prednisone—ankylosing spondylitis	6.69e-05	0.00102	CcSEcCtD
Zoledronate—Myalgia—Methotrexate—ankylosing spondylitis	6.62e-05	0.00101	CcSEcCtD
Zoledronate—Arthralgia—Methotrexate—ankylosing spondylitis	6.62e-05	0.00101	CcSEcCtD
Zoledronate—Chest pain—Methotrexate—ankylosing spondylitis	6.62e-05	0.00101	CcSEcCtD
Zoledronate—Decreased appetite—Prednisone—ankylosing spondylitis	6.6e-05	0.00101	CcSEcCtD
Zoledronate—Rash—Prednisolone—ankylosing spondylitis	6.59e-05	0.00101	CcSEcCtD
Zoledronate—Dermatitis—Prednisolone—ankylosing spondylitis	6.58e-05	0.00101	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	6.58e-05	0.00101	CcSEcCtD
Zoledronate—Diarrhoea—Methylprednisolone—ankylosing spondylitis	6.56e-05	0.001	CcSEcCtD
Zoledronate—Fatigue—Prednisone—ankylosing spondylitis	6.55e-05	0.001	CcSEcCtD
Zoledronate—Headache—Prednisolone—ankylosing spondylitis	6.55e-05	0.001	CcSEcCtD
Zoledronate—Discomfort—Methotrexate—ankylosing spondylitis	6.54e-05	0.001	CcSEcCtD
Zoledronate—Constipation—Prednisone—ankylosing spondylitis	6.5e-05	0.000994	CcSEcCtD
Zoledronate—Confusional state—Methotrexate—ankylosing spondylitis	6.4e-05	0.000979	CcSEcCtD
Zoledronate—Dizziness—Triamcinolone—ankylosing spondylitis	6.36e-05	0.000972	CcSEcCtD
Zoledronate—Anaphylactic shock—Methotrexate—ankylosing spondylitis	6.35e-05	0.000971	CcSEcCtD
Zoledronate—Dizziness—Methylprednisolone—ankylosing spondylitis	6.34e-05	0.00097	CcSEcCtD
Zoledronate—Infection—Methotrexate—ankylosing spondylitis	6.31e-05	0.000965	CcSEcCtD
Zoledronate—Feeling abnormal—Prednisone—ankylosing spondylitis	6.26e-05	0.000958	CcSEcCtD
Zoledronate—Asthenia—Dexamethasone—ankylosing spondylitis	6.26e-05	0.000957	CcSEcCtD
Zoledronate—Asthenia—Betamethasone—ankylosing spondylitis	6.26e-05	0.000957	CcSEcCtD
Zoledronate—Nervous system disorder—Methotrexate—ankylosing spondylitis	6.23e-05	0.000952	CcSEcCtD
Zoledronate—Thrombocytopenia—Methotrexate—ankylosing spondylitis	6.22e-05	0.000951	CcSEcCtD
Zoledronate—Gastrointestinal pain—Prednisone—ankylosing spondylitis	6.21e-05	0.00095	CcSEcCtD
Zoledronate—Nausea—Prednisolone—ankylosing spondylitis	6.21e-05	0.00095	CcSEcCtD
Zoledronate—Pruritus—Betamethasone—ankylosing spondylitis	6.17e-05	0.000944	CcSEcCtD
Zoledronate—Pruritus—Dexamethasone—ankylosing spondylitis	6.17e-05	0.000944	CcSEcCtD
Zoledronate—Skin disorder—Methotrexate—ankylosing spondylitis	6.17e-05	0.000943	CcSEcCtD
Zoledronate—Hyperhidrosis—Methotrexate—ankylosing spondylitis	6.14e-05	0.000939	CcSEcCtD
Zoledronate—Vomiting—Triamcinolone—ankylosing spondylitis	6.11e-05	0.000935	CcSEcCtD
Zoledronate—Vomiting—Methylprednisolone—ankylosing spondylitis	6.1e-05	0.000933	CcSEcCtD
Zoledronate—Rash—Triamcinolone—ankylosing spondylitis	6.06e-05	0.000927	CcSEcCtD
Zoledronate—Dermatitis—Triamcinolone—ankylosing spondylitis	6.06e-05	0.000926	CcSEcCtD
Zoledronate—Anorexia—Methotrexate—ankylosing spondylitis	6.05e-05	0.000926	CcSEcCtD
Zoledronate—Rash—Methylprednisolone—ankylosing spondylitis	6.05e-05	0.000925	CcSEcCtD
Zoledronate—Dermatitis—Methylprednisolone—ankylosing spondylitis	6.04e-05	0.000924	CcSEcCtD
Zoledronate—Urticaria—Prednisone—ankylosing spondylitis	6.03e-05	0.000923	CcSEcCtD
Zoledronate—Headache—Triamcinolone—ankylosing spondylitis	6.02e-05	0.000921	CcSEcCtD
Zoledronate—Headache—Methylprednisolone—ankylosing spondylitis	6.01e-05	0.000919	CcSEcCtD
Zoledronate—Abdominal pain—Prednisone—ankylosing spondylitis	6e-05	0.000919	CcSEcCtD
Zoledronate—Body temperature increased—Prednisone—ankylosing spondylitis	6e-05	0.000919	CcSEcCtD
Zoledronate—Diarrhoea—Dexamethasone—ankylosing spondylitis	5.97e-05	0.000913	CcSEcCtD
Zoledronate—Diarrhoea—Betamethasone—ankylosing spondylitis	5.97e-05	0.000913	CcSEcCtD
Zoledronate—Hypotension—Methotrexate—ankylosing spondylitis	5.93e-05	0.000907	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	5.78e-05	0.000885	CcSEcCtD
Zoledronate—Dizziness—Betamethasone—ankylosing spondylitis	5.77e-05	0.000882	CcSEcCtD
Zoledronate—Dizziness—Dexamethasone—ankylosing spondylitis	5.77e-05	0.000882	CcSEcCtD
Zoledronate—Insomnia—Methotrexate—ankylosing spondylitis	5.74e-05	0.000878	CcSEcCtD
Zoledronate—Nausea—Triamcinolone—ankylosing spondylitis	5.71e-05	0.000873	CcSEcCtD
Zoledronate—Paraesthesia—Methotrexate—ankylosing spondylitis	5.7e-05	0.000872	CcSEcCtD
Zoledronate—Nausea—Methylprednisolone—ankylosing spondylitis	5.7e-05	0.000872	CcSEcCtD
Zoledronate—Dyspnoea—Methotrexate—ankylosing spondylitis	5.66e-05	0.000866	CcSEcCtD
Zoledronate—Somnolence—Methotrexate—ankylosing spondylitis	5.64e-05	0.000863	CcSEcCtD
Zoledronate—Hypersensitivity—Prednisone—ankylosing spondylitis	5.6e-05	0.000856	CcSEcCtD
Zoledronate—Dyspepsia—Methotrexate—ankylosing spondylitis	5.59e-05	0.000855	CcSEcCtD
Zoledronate—Vomiting—Betamethasone—ankylosing spondylitis	5.55e-05	0.000848	CcSEcCtD
Zoledronate—Vomiting—Dexamethasone—ankylosing spondylitis	5.55e-05	0.000848	CcSEcCtD
Zoledronate—Decreased appetite—Methotrexate—ankylosing spondylitis	5.52e-05	0.000844	CcSEcCtD
Zoledronate—Rash—Dexamethasone—ankylosing spondylitis	5.5e-05	0.000841	CcSEcCtD
Zoledronate—Rash—Betamethasone—ankylosing spondylitis	5.5e-05	0.000841	CcSEcCtD
Zoledronate—Dermatitis—Dexamethasone—ankylosing spondylitis	5.49e-05	0.000841	CcSEcCtD
Zoledronate—Dermatitis—Betamethasone—ankylosing spondylitis	5.49e-05	0.000841	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	5.48e-05	0.000838	CcSEcCtD
Zoledronate—Fatigue—Methotrexate—ankylosing spondylitis	5.47e-05	0.000837	CcSEcCtD
Zoledronate—Headache—Dexamethasone—ankylosing spondylitis	5.46e-05	0.000836	CcSEcCtD
Zoledronate—Headache—Betamethasone—ankylosing spondylitis	5.46e-05	0.000836	CcSEcCtD
Zoledronate—Asthenia—Prednisone—ankylosing spondylitis	5.45e-05	0.000834	CcSEcCtD
Zoledronate—Pain—Methotrexate—ankylosing spondylitis	5.43e-05	0.00083	CcSEcCtD
Zoledronate—Pruritus—Prednisone—ankylosing spondylitis	5.37e-05	0.000822	CcSEcCtD
Zoledronate—Feeling abnormal—Methotrexate—ankylosing spondylitis	5.23e-05	0.0008	CcSEcCtD
Zoledronate—Diarrhoea—Prednisone—ankylosing spondylitis	5.2e-05	0.000795	CcSEcCtD
Zoledronate—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	5.19e-05	0.000794	CcSEcCtD
Zoledronate—Nausea—Dexamethasone—ankylosing spondylitis	5.18e-05	0.000793	CcSEcCtD
Zoledronate—Nausea—Betamethasone—ankylosing spondylitis	5.18e-05	0.000793	CcSEcCtD
Zoledronate—Urticaria—Methotrexate—ankylosing spondylitis	5.04e-05	0.000771	CcSEcCtD
Zoledronate—Dizziness—Prednisone—ankylosing spondylitis	5.02e-05	0.000768	CcSEcCtD
Zoledronate—Abdominal pain—Methotrexate—ankylosing spondylitis	5.02e-05	0.000768	CcSEcCtD
Zoledronate—Body temperature increased—Methotrexate—ankylosing spondylitis	5.02e-05	0.000768	CcSEcCtD
Zoledronate—Vomiting—Prednisone—ankylosing spondylitis	4.83e-05	0.000739	CcSEcCtD
Zoledronate—Rash—Prednisone—ankylosing spondylitis	4.79e-05	0.000733	CcSEcCtD
Zoledronate—Dermatitis—Prednisone—ankylosing spondylitis	4.78e-05	0.000732	CcSEcCtD
Zoledronate—Headache—Prednisone—ankylosing spondylitis	4.76e-05	0.000728	CcSEcCtD
Zoledronate—Hypersensitivity—Methotrexate—ankylosing spondylitis	4.68e-05	0.000715	CcSEcCtD
Zoledronate—Asthenia—Methotrexate—ankylosing spondylitis	4.55e-05	0.000697	CcSEcCtD
Zoledronate—Nausea—Prednisone—ankylosing spondylitis	4.51e-05	0.00069	CcSEcCtD
Zoledronate—Pruritus—Methotrexate—ankylosing spondylitis	4.49e-05	0.000687	CcSEcCtD
Zoledronate—Diarrhoea—Methotrexate—ankylosing spondylitis	4.34e-05	0.000664	CcSEcCtD
Zoledronate—Dizziness—Methotrexate—ankylosing spondylitis	4.2e-05	0.000642	CcSEcCtD
Zoledronate—Vomiting—Methotrexate—ankylosing spondylitis	4.04e-05	0.000617	CcSEcCtD
Zoledronate—Rash—Methotrexate—ankylosing spondylitis	4e-05	0.000612	CcSEcCtD
Zoledronate—Dermatitis—Methotrexate—ankylosing spondylitis	4e-05	0.000612	CcSEcCtD
Zoledronate—Headache—Methotrexate—ankylosing spondylitis	3.98e-05	0.000608	CcSEcCtD
Zoledronate—Nausea—Methotrexate—ankylosing spondylitis	3.77e-05	0.000577	CcSEcCtD
